Retrospective Analysis of Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer
Targeted chemotherapy has gradually become the mainstay of cancer treatment in present day.
Targeted medications such as trastuzumab, bevacizumab and lapatinib have recently been more
extensively adopted for many cancers, particularly breast cancer. Among these targeted
medications, bevacizumab is a monoclonal antibody acting on vascular endothelial growth
factor receptor and it works by preventing the formation of new blood vessels
(angiogenesis). Published articles indicated that monotherapy of bevacizumab on breast
cancer showed only a 9-17% response rate, while combining with paclitaxel, the treatment
outcome appeared to improve progression-free survival and the objective response rate. We
are curious about the additive effect of bevacizumab on conventional chemotherapy, the
toxicities induced when combined target therapy with conventional chemotherapy and the
duration of remission that these treatment could achieve. In this study, we utilized
bevacizumab, docetaxel plus cisplatin for metastatic breast cancer patients and furthermore,
we are evaluated the treatment response, toxicities and duration of remission as our main
goals.
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response Rate
every 3 months
Yes
Cheng-Jeng Tai, M.D.
Principal Investigator
Section of Hematology-Oncology, Department of Medicine, Taipei Medical University Hospital
United States: Food and Drug Administration
TMUH-01-09-09
NCT01025349
January 2005
September 2009
Name | Location |
---|